ScreenerHero

SVRASavara Inc.

NAS · US · Healthcare · Biotechnology · savarapharma.com
5.590USD+0.18%Mkt Cap: 1.15B $P/E: —

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulati…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.15B $
Enterprise Value1.25B $
Revenue (TTM)—
Gross Profit-86.84M $
Net Income (TTM)-118.84M $
Revenue/Share—
Last Price5.590 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees70
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS8051111016
Valuation
P/E (Trailing)—
P/E (Forward)-17.60
PEG—
EV/EBITDA-8.77
EV/Revenue—
P/S—
P/B7.91
EPS (TTM)-0.57
EPS (Forward)-0.31
52W Range
2.92065% of range7.005
52W High7.005 USD
52W Low2.920 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.50%
ROA-46.89%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-101.04M $
CapEx (TTM)22.00K $
FCF Margin—
FCF Yield-4.99%
Net Debt-144.41M $
Net Debt/EBITDA1.01
Balance Sheet
Debt/Equity0.15
Current Ratio10.13
Quick Ratio9.99
Book Value/Sh0.6940 USD
Cash/Share0.6880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateApr 28, 2017
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.94 USD
Upside (mean)+95.7%
Target Range9.000 USD – 16.00 USD
$9.000+95.7% to mean$16.00
# Analysts8
Ownership
Shares Out.204.93M
Float129.69M
Insiders2.59%
Institutions106.45%
Short Interest
Short Ratio20.7d
Short % Float21.01%
Short % Out.17.97%
Shares Short36.82M
Short (prev mo.)32.03M
Technical
SMA 505.657 (-1.2%)
SMA 2005.511 (+1.4%)
Beta0.26
S&P 52W Chg18.16%
Avg Vol (30d)1.59M
Avg Vol (10d)1.53M
Technical Indicators
RSI (14)50.7
MACD-0.0319
MACD Signal-0.0320
MACD Hist.+0.0001
BB Upper5.864 USD
BB Middle5.518 USD
BB Lower5.172 USD
BB Width12.53%
ATR (14)0.2738 USD
Vol Ratio (20d)0.97x